Date: 2014-10-15
Type of information: Grant
Company: TC BioPharm (UK)
Investors: Scottish Enterprise (UK)
Amount: £100,000 (€125733)
Funding type: grant
Planned used: The grant has been awarded to TC BioPharm to enable the company to perform innovative research evaluating microRNA expression in cancer patients. TC Biopharm will use the SMART: SCOTLAND grant to collaborate with Sistemic (Glasgow), and develop novel bio-marker probes of biomarkers designed to provide valuable information on individual patient responses to TCB’s innovative cell therapy product. TC Biopharma’s technology uses patients’ own immune cells grown in culture to target cancer, and has a safe history of use based on the treatment of numerous patients by Medinet in Japan. Further to scientific advice from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) which has provided a clear roadmap to clinical studies, the Company plans to treat the first cohort of patients during 2015, working alongside established cancer clinics in Glasgow, Southampton and Birmingham. Leveraging Sistemic’s proven expertise in the field of microRNA (miRNA) detection systems, the two companies aim to provide clinicians and patients with a unique treatment platform which combines innovative cell therapy with theranostic feedback.
Others: * On October 15, 2014, Scottish Enterprise, Scotland\'s main economic development agency, has awarded TC BioPharm (TCB) a £100,000 SMART: SCOTLAND feasibility study grant, to develop biomarkers capable of predicting treatment responses in cancer patients. TC BioPharm has recently completed its Clinical Manufacturing Facility at Maxim Park, Glasgow. Comprising offices, two cleanrooms, quality control suites and development laboratories, the total footprint extends to 5,000 sqft, of which 3,500 sqft is designed to support manufacture of clinical grade product. TCB worked closely with WH Partnership (Gateshead), one of the UK’s leading cleanroom design, engineering and construction companies, to complete the build in record-time. In addition to building the facility, the Board of WH Partnership elected to invest in TCB alongside the Scottish Investment Bank. Based in North Lanarkshire at the Eastern end of Glasgow’s BioCorridor, the new cleanroom facility will require an IMP (Investigational Medicinal Product) licence from the MHRA before clinical product can be made.
Therapeutic area: Cancer - Oncology
